Advanced gastric or gastroesophageal junction (G/gej) adenocarcinoma

Clinical trials for Advanced gastric or gastroesophageal junction (G/gej) adenocarcinoma explained in plain language.

Never miss a new study

Get alerted when new Advanced gastric or gastroesophageal junction (G/gej) adenocarcinoma trials appear

Sign up with your email to follow new studies for Advanced gastric or gastroesophageal junction (G/gej) adenocarcinoma, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet finished but already full! 1

New cocktail aims to shrink Hard-to-Treat stomach tumors

Disease control Ongoing

This phase 2 trial is testing a combination of three drugs—anlotinib, TQB2450, and the SOX chemotherapy regimen—as a first treatment for advanced stomach or gastroesophageal junction cancer that has low PD-L1 expression. The study involves 37 participants and aims to see how well…

Matched conditions: ADVANCED GASTRIC OR GASTROESOPHAGEAL JUNCTION (G/GEJ) ADENOCARCINOMA

Phase 2 • Sponsor: Yongxu Jia • Aim: Disease control

Last updated Jun 27, 2026 12:04 UTC

Advanced gastric or gastroesophageal junction (G/gej) adenocarcinoma

Get alerted when new Advanced gastric or gastroesophageal junction (G/gej) adenocarcinoma trials appear

New cocktail aims to shrink Hard-to-Treat stomach tumors